A pilot open series of lamotrigine in DBT-treated eating disorders characterized by significant affective dysregulation and poor impulse control

Table 1 Sample Characteristics

ID	Age	Ethnicity	Race	BMI (kg/m2)	Diagnosis at Admission	Days on Lamotrigine at Baseline Assessment	Total Days on Lamotrigine	Final Lamotrigine Dose (mg/day)	Concurrent Medications
1	28	Non-Hispanic	Black	26.3	EDNOS^a	−2	223	150	quetiapine XR, bupropion XL, levomilnacipran
2	23	Non-Hispanic	White	20.2	EDNOS^b	−5	246	200	duloxetine, trazodone
3	41	Non-Hispanic	White	21.9	EDNOS^c	−4	253	100	escitalopram
4	42	Hispanic	Other	28.3	BN	1	190	100	venlafaxine XR, naltrexone
5	18	Non-Hispanic	White	19.7	AN-BP	1	86	200	sertraline, gabapentin
6	31	Non-Hispanic	White	20.1	AN-BP	1	85	200	gabapentin, naltrexone
7	25	Non-Hispanic	White	19.1	AN-R	0	102	200	duloxetine, sertraline^d
8	31	Hispanic	Other	22.3	AN-BP	0	71	100	fluoxetine
9	32	Non-Hispanic	Other	25.7	BN	1	71	200	duloxetine

^aHigh-normal to mildly overweight with restrictive eating and purging; ^bMildly underweight AN with alternating severe restrictive eating, bingeing, and occasional purging; ^cLifetime history of mostly BN with episodes of AN-BP. During period of study, most characteristic of low-normal-weight AN-P; ^dDuloxetine was concurrent with lamotrigine for one month and was subsequently replaced with sertraline in the second month. In the third month, lamotrigine was the only medication prescribed. BMI = body mass index; AN-BP = anorexia nervosa, binge-eating/purging subtype; EDNOS = eating disorder not otherwise specified; BN = bulimia nervosa